The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 192 participants.

Also called NCT05386186

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 192 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05386186
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05386186. Randomized; no masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2023-10-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Glimepiride Compared With Sitagliptin as an add-on Therapy to Metformin in Severe Insulin Deficiency Diabetes
Condition
Diabetes Mellitus, Type 2
Condition
Severe Insulin Deficient Diabetes
Intervention (Drug)
Glimepiride
Intervention (Drug)
Sitagliptin
Lead sponsor
Peking University People's Hospital (class: other)
Collaborator
Peking University First Hospital (class: other)
Collaborator
Jiangsu Province Geriatric Institute (class: not stated)

Record details

Record id
cardio:ct-nct05386186
Content hash
c6ba827bb3ab0470ebb54d1b6c39d2bc2cc1f4deff0555eba3996eb921e99240